Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer.

作者: Atul Batra , Rodrigo Rigo , Malek B. Hannouf , Winson Y. Cheung

DOI: 10.1016/J.CLCC.2020.09.006

关键词:

摘要: Abstract Background Use of fluoropyrimidine-based therapy in patients with metastatic colorectal cancer is associated significant toxicities. This study aimed to assess the safety and efficacy raltitrexed use who developed toxicities after treatment. Patients Methods We identified were treated raltitrexed-based systemic developing serious adverse events treatment a large Canadian province from 2004 2018. Demographic, tumor, characteristics retrieved electronic medical records. Progression-free overall survival assessed start therapy. Results A total 86 for study. The median age was 66.5 years, 58.1% men. primary site right, left, transverse colon 38.4%, 27.9%, 9.3%, respectively. remaining 24.4% had rectal cancer. Among all patients, 43.0% received more than 2 prior therapies, 37.6% previous cardiotoxicity progression-free 8.5 10.2 months, On multivariable Cox regression model, left-sided (hazard ratio [HR], 0.33; 95% confidence interval [CI], 0.12-0.97; P = .044) Eastern Cooperative Oncology Group performance status 0/1 (HR, 0.10; CI, 0.01-0.82; .032) longer survival, whereas left-sidedness only factor that predicted 0.30; 0.10-0.88; .029). Raltitrexed well-tolerated common included anemia 41.7% chemotherapy-induced nausea vomiting 27.4%. Most grade 1/2, but 16.7% experienced 3. There no cardiac treatment-related deaths. Conclusions previously effective well-tolerated.

参考文章(53)
Robert J Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio Garcia-Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu, Alberto Sobrero, Eveline Boucher, Marc Peeters, Ben Tran, Heinz-Josef Lenz, Alberto Zaniboni, Howard Hochster, James M Cleary, Hans Prenen, Fabio Benedetti, Hirokazu Mizuguchi, Lukas Makris, Masanobu Ito, Atsushi Ohtsu, None, Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer The New England Journal of Medicine. ,vol. 372, pp. 1909- 1919 ,(2015) , 10.1056/NEJMOA1414325
Catherine Lombard-Bohas, Panayota Tsibiribi, Jacques Descotes, Quadiri Timour, Bernard Bui-Xuan, Majda Belkhiria, Alain Tabib, Cécile Barel, Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease Bulletin Du Cancer. ,vol. 93, pp. 10027- 10030 ,(2006)
M de Forni, M C Malet-Martino, P Jaillais, R E Shubinski, J M Bachaud, L Lemaire, P Canal, C Chevreau, D Carrié, P Soulié, Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. Journal of Clinical Oncology. ,vol. 10, pp. 1795- 1801 ,(1992) , 10.1200/JCO.1992.10.11.1795
André B P van Kuilenburg, Lida Zoetekouw, Koichi Matsuda, Frank Baas, Albert H van Gennip, Rutger Meinsma, Bernard A Zonnenberg, Nanaya Tamaki, Dihydropyrimidinase Deficiency and Severe 5-Fluorouracil Toxicity Clinical Cancer Research. ,vol. 9, pp. 4363- 4367 ,(2003)
Ivan Popov, Alfredo Carrato, Alberto Sobrero, Mark Vincent, David Kerr, Roberto Labianca, Angelo Raffaele Bianco, Mostafa El-Serafi, Laurent Bedenne, Bernard Paillot, Enrico Mini, Evaristo Sanches, John Welch, Laurence Collette, Michel Praet, Jacques Wils, Raltitrexed (Tomudex®) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) European Journal of Cancer. ,vol. 44, pp. 2204- 2211 ,(2008) , 10.1016/J.EJCA.2008.07.002
G Cianci, M F Morelli, K Cannita, R Morese, E Ricevuto, Z C Di Rocco, G Porzio, P Lanfiuti Baldi, C Ficorella, Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity British Journal of Cancer. ,vol. 88, pp. 1507- 1509 ,(2003) , 10.1038/SJ.BJC.6600967
Barry Iacopetta, Are there two sides to colorectal cancer International Journal of Cancer. ,vol. 101, pp. 403- 408 ,(2002) , 10.1002/IJC.10635
J Feliu, , C Castañón, A Salud, J R Mel, P Escudero, A Pelegrín, L López-Gómez, M Ruiz, E González, F Juárez, J Lizón, J Castro, M González-Barón, Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer British Journal of Cancer. ,vol. 93, pp. 1230- 1235 ,(2005) , 10.1038/SJ.BJC.6602860
Luigi Ricciardiello, Claudio Ceccarelli, Graziella Angiolini, Milena Pariali, Pasquale Chieco, Paola Paterini, Guido Biasco, Giuseppe N. Martinelli, Enrico Roda, Franco Bazzoli, High Thymidylate Synthase Expression in Colorectal Cancer with Microsatellite Instability: Implications for Chemotherapeutic Strategies Clinical Cancer Research. ,vol. 11, pp. 4234- 4240 ,(2005) , 10.1158/1078-0432.CCR-05-0141